Legal Representation
Attorney
Ann Lamport Hammitte
USPTO Deadlines
Application History
29 eventsDate | Code | Type | Description |
---|---|---|---|
Nov 7, 2011 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
Nov 7, 2011 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |
Apr 13, 2011 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
Apr 12, 2011 | EX3G | S | SOU EXTENSION 3 GRANTED |
Apr 5, 2011 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Apr 5, 2011 | EXT3 | S | SOU EXTENSION 3 FILED |
Oct 8, 2010 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
Oct 7, 2010 | EX2G | S | SOU EXTENSION 2 GRANTED |
Oct 5, 2010 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
Oct 5, 2010 | EXT2 | S | SOU EXTENSION 2 FILED |
May 4, 2010 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED |
May 3, 2010 | EX1G | S | SOU EXTENSION 1 GRANTED |
Apr 30, 2010 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Apr 7, 2010 | I | PAPER RECEIVED | |
Apr 6, 2010 | EXT1 | S | SOU EXTENSION 1 FILED |
Oct 6, 2009 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT |
Jul 14, 2009 | PUBO | A | PUBLISHED FOR OPPOSITION |
Jun 24, 2009 | NPUB | O | NOTICE OF PUBLICATION |
Jun 10, 2009 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
Jun 8, 2009 | ALIE | A | ASSIGNED TO LIE |
Jun 8, 2009 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Jun 8, 2009 | ACEC | I | AMENDMENT FROM APPLICANT ENTERED |
Jun 8, 2009 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Jun 5, 2009 | I | PAPER RECEIVED | |
May 5, 2009 | CNRT | F | NON-FINAL ACTION MAILED |
May 4, 2009 | CNRT | R | NON-FINAL ACTION WRITTEN |
Apr 29, 2009 | DOCK | D | ASSIGNED TO EXAMINER |
Feb 13, 2009 | NWAP | I | NEW APPLICATION ENTERED |
Feb 13, 2009 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, lipid delivery platforms and formulations for RNA therapeutics for use in human and veterinary medicine; pharmaceutical preparations, namely, lipids and formulations for delivery of RNA therapeutics for use in human and veterinary medicine
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005